FN1 and pulmonary hypertension, primary, 1: Formononetin (FN), a bioactive isoflavone (Figure 1A), exhibits pleiotropic properties including estrogen receptor modulation, antifibrotic activity, and antioxidant effects (8, 9), positioning it as a compelling candidate for PHT management.